Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cymer, Inc. (“Cymer” or the “Company”) (Nasdaq: CYMI) relating to the proposed acquisition by ASML Holding NV. (“ASML”).
Under the terms of the transaction, Cymer shareholders will receive only a fixed 1.1502 shares of ASML ordinary stock plus $20.00 in cash for each share on Cymer common stock they own. The transaction values Cymer at approximately $81.64. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Cymer for not acting in the Company’s shareholders' best interests in connection with the sale process to ASML. Cymer has reported second quarter of 2012 results which beat analyst estimates by 600%. In addition, this marked the seventh time in the previous eight quarters that Cymer’s revenue exceeded analyst expectations. As a result, the transaction may undervalue the Company and prevent Cymer shareholders from participating in Cymer’s continued growth.
If you own shares of Cymer stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at
, by calling toll free 877-LEGAL-90.